Cargando…

The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression

The transcription factor NRF2 is the major mediator of oxidative stress responses and is closely connected to therapy resistance in tumors harboring activating mutations in the NRF2 pathway. In melanoma, such mutations are rare, and it is unclear to what extent melanomas rely on NRF2. Here we show t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jessen, Christina, Kreß, Julia K. C., Baluapuri, Apoorva, Hufnagel, Anita, Schmitz, Werner, Kneitz, Susanne, Roth, Sabine, Marquardt, André, Appenzeller, Silke, Ade, Carsten P., Glutsch, Valerie, Wobser, Marion, Friedmann-Angeli, José Pedro, Mosteo, Laura, Goding, Colin R., Schilling, Bastian, Geissinger, Eva, Wolf, Elmar, Meierjohann, Svenja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605435/
https://www.ncbi.nlm.nih.gov/pubmed/32978520
http://dx.doi.org/10.1038/s41388-020-01477-8
_version_ 1783604302367948800
author Jessen, Christina
Kreß, Julia K. C.
Baluapuri, Apoorva
Hufnagel, Anita
Schmitz, Werner
Kneitz, Susanne
Roth, Sabine
Marquardt, André
Appenzeller, Silke
Ade, Carsten P.
Glutsch, Valerie
Wobser, Marion
Friedmann-Angeli, José Pedro
Mosteo, Laura
Goding, Colin R.
Schilling, Bastian
Geissinger, Eva
Wolf, Elmar
Meierjohann, Svenja
author_facet Jessen, Christina
Kreß, Julia K. C.
Baluapuri, Apoorva
Hufnagel, Anita
Schmitz, Werner
Kneitz, Susanne
Roth, Sabine
Marquardt, André
Appenzeller, Silke
Ade, Carsten P.
Glutsch, Valerie
Wobser, Marion
Friedmann-Angeli, José Pedro
Mosteo, Laura
Goding, Colin R.
Schilling, Bastian
Geissinger, Eva
Wolf, Elmar
Meierjohann, Svenja
author_sort Jessen, Christina
collection PubMed
description The transcription factor NRF2 is the major mediator of oxidative stress responses and is closely connected to therapy resistance in tumors harboring activating mutations in the NRF2 pathway. In melanoma, such mutations are rare, and it is unclear to what extent melanomas rely on NRF2. Here we show that NRF2 suppresses the activity of the melanocyte lineage marker MITF in melanoma, thereby reducing the expression of pigmentation markers. Intriguingly, we furthermore identified NRF2 as key regulator of immune-modulating genes, linking oxidative stress with the induction of cyclooxygenase 2 (COX2) in an ATF4-dependent manner. COX2 is critical for the secretion of prostaglandin E2 and was strongly induced by H(2)O(2) or TNFα only in presence of NRF2. Induction of MITF and depletion of COX2 and PGE2 were also observed in NRF2-deleted melanoma cells in vivo. Furthermore, genes corresponding to the innate immune response such as RSAD2 and IFIH1 were strongly elevated in absence of NRF2 and coincided with immune evasion parameters in human melanoma datasets. Even in vitro, NRF2 activation or prostaglandin E2 supplementation blunted the induction of the innate immune response in melanoma cells. Transcriptome analyses from lung adenocarcinomas indicate that the observed link between NRF2 and the innate immune response is not restricted to melanoma.
format Online
Article
Text
id pubmed-7605435
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-76054352020-11-12 The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression Jessen, Christina Kreß, Julia K. C. Baluapuri, Apoorva Hufnagel, Anita Schmitz, Werner Kneitz, Susanne Roth, Sabine Marquardt, André Appenzeller, Silke Ade, Carsten P. Glutsch, Valerie Wobser, Marion Friedmann-Angeli, José Pedro Mosteo, Laura Goding, Colin R. Schilling, Bastian Geissinger, Eva Wolf, Elmar Meierjohann, Svenja Oncogene Article The transcription factor NRF2 is the major mediator of oxidative stress responses and is closely connected to therapy resistance in tumors harboring activating mutations in the NRF2 pathway. In melanoma, such mutations are rare, and it is unclear to what extent melanomas rely on NRF2. Here we show that NRF2 suppresses the activity of the melanocyte lineage marker MITF in melanoma, thereby reducing the expression of pigmentation markers. Intriguingly, we furthermore identified NRF2 as key regulator of immune-modulating genes, linking oxidative stress with the induction of cyclooxygenase 2 (COX2) in an ATF4-dependent manner. COX2 is critical for the secretion of prostaglandin E2 and was strongly induced by H(2)O(2) or TNFα only in presence of NRF2. Induction of MITF and depletion of COX2 and PGE2 were also observed in NRF2-deleted melanoma cells in vivo. Furthermore, genes corresponding to the innate immune response such as RSAD2 and IFIH1 were strongly elevated in absence of NRF2 and coincided with immune evasion parameters in human melanoma datasets. Even in vitro, NRF2 activation or prostaglandin E2 supplementation blunted the induction of the innate immune response in melanoma cells. Transcriptome analyses from lung adenocarcinomas indicate that the observed link between NRF2 and the innate immune response is not restricted to melanoma. Nature Publishing Group UK 2020-09-25 2020 /pmc/articles/PMC7605435/ /pubmed/32978520 http://dx.doi.org/10.1038/s41388-020-01477-8 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Jessen, Christina
Kreß, Julia K. C.
Baluapuri, Apoorva
Hufnagel, Anita
Schmitz, Werner
Kneitz, Susanne
Roth, Sabine
Marquardt, André
Appenzeller, Silke
Ade, Carsten P.
Glutsch, Valerie
Wobser, Marion
Friedmann-Angeli, José Pedro
Mosteo, Laura
Goding, Colin R.
Schilling, Bastian
Geissinger, Eva
Wolf, Elmar
Meierjohann, Svenja
The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression
title The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression
title_full The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression
title_fullStr The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression
title_full_unstemmed The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression
title_short The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression
title_sort transcription factor nrf2 enhances melanoma malignancy by blocking differentiation and inducing cox2 expression
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605435/
https://www.ncbi.nlm.nih.gov/pubmed/32978520
http://dx.doi.org/10.1038/s41388-020-01477-8
work_keys_str_mv AT jessenchristina thetranscriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT kreßjuliakc thetranscriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT baluapuriapoorva thetranscriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT hufnagelanita thetranscriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT schmitzwerner thetranscriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT kneitzsusanne thetranscriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT rothsabine thetranscriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT marquardtandre thetranscriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT appenzellersilke thetranscriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT adecarstenp thetranscriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT glutschvalerie thetranscriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT wobsermarion thetranscriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT friedmannangelijosepedro thetranscriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT mosteolaura thetranscriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT godingcolinr thetranscriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT schillingbastian thetranscriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT geissingereva thetranscriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT wolfelmar thetranscriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT meierjohannsvenja thetranscriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT jessenchristina transcriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT kreßjuliakc transcriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT baluapuriapoorva transcriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT hufnagelanita transcriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT schmitzwerner transcriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT kneitzsusanne transcriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT rothsabine transcriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT marquardtandre transcriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT appenzellersilke transcriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT adecarstenp transcriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT glutschvalerie transcriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT wobsermarion transcriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT friedmannangelijosepedro transcriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT mosteolaura transcriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT godingcolinr transcriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT schillingbastian transcriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT geissingereva transcriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT wolfelmar transcriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression
AT meierjohannsvenja transcriptionfactornrf2enhancesmelanomamalignancybyblockingdifferentiationandinducingcox2expression